Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors
NCT02323880Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Oct 2015
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in solid tumor, central nervous system tumor and high-grade glioma (HGG), sponsored by Children's Oncology Group. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and 1 more. Started Oct 2015; status: completed.
02
Drugs
selinexor
03
Conditions
solid tumorcentral nervous system tumorhigh-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02323880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323880.